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 US MLE TEST 
A 65-year-old man with a history of ischemic cardiomyopathy, 
congestive heart failure, diabetes mellitus, and chronic kidney 
disease presents to the emergency room with progressive 
dyspnea on exertion and weight gain for 8 days. Vitals signs are 
T 99.0, HR 110, BP 130/90, RR 24, SpO2 94% on room air. 
Physical examination reveals an S3 gallop, 2+ peripheral pitting 
edema, and marked jugular venous distention. Laboratory 
results show a serum creatinine of 1.2 mg/dL compared with 
the patient's normal baseline value of 1.1 mg/dL. The patient's 
chest radiograph is shown in Image A. A serum troponin is 
drawn and found to be 0.04 ng/mL. Which of the following 
medications is indicated first in the care of this patient? 
1.  Enalapril, 2.  Furosemide, 3.  Dobutamine, 4.  Hydralazine,  
5.  Dopamine 
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
 US MLE TEST 
Correct Answer 2:  This patient is volume-overloaded and requires a 
diuretic to decrease preload to his heart. Furosemide, a loop-diuretic, 
will decrease preload and is the best choice. (Note that the other drugs 
listed are used for chronic CHF management and/or in the case of CHF 
refractory to furosemide treatment.)  
Incorrect Answers: 
1: Enalapril is an ACE inhibitor that decreased mortality when used in 
the treatment of systolic heart failure. It is not the most appropriate first 
line agent for ADHF in this patient., 3: Dobutamine is sympathomimetic 
used in the treatment of heart failure, but furosemide is a more 
appropriate first line agent in this patient., 4: Hydralazine is used in the 
treatment of hypertension and is not the most appropriate first line 
agent in the treatment of this patient., 5: Dopamine is an ionotropic and 
chronotropic drug used in the treatment of heart failure. However, 
furosemide is a more appropriate first line agent in this patient.  
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
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Definition 1 
• (Congestive) heart failure (HF) is a clinical 
syndrome caused by a structural and/or 
functional cardiac abnormality, resulting in a 
reduced cardiac output and/or elevated 
intracardiac pressures at rest or during stress, 
characterized by typical symptoms (e.g. 
breathlessness, ankle swelling and fatigue) 
that may be accompanied by signs (e.g. 
elevated jugular venous pressure, pulmonary 
crackles and peripheral oedema).  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Definition 2 
• Before clinical symptoms become apparent, 
patients can present with asymptomatic 
structural or functional cardiac abnormalities 
(asymptomatic systolic  left ventricle (LV) 
dysfunction), which recognition  as precursors 
of HF is important  for starting its treatment as 
soon as possible in deal to reduce patients 
mortality. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Epidemiology   
(Hear Failure around the World) 1 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
• The prevalence of HF depends on the 
definition applied, but is approximately 1–2% 
of the adult population in developed 
countries, rising to ≥10% among people >70 
years of age. 
• Among people >65 years of age presenting to 
primary care with breathlessness on exertion, 
one in six will have unrecognized HF (mainly 
HFpEF).  
Epidemiology   
(Hear Failure around the World) 2 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
• The lifetime risk of HF at age 55 years is 33% 
for men and 28% for women. 
• The proportion of patients with HFpEF ranges 
from 22 to 73%, depending on the definition 
applied, the clinical setting (primary care, 
hospital clinic, hospital admission), age and 
sex of the population, previous myocardial 
infarction and the year of publication. 
Epidemiology   
(The Heart Failure Epidemic) 
medicographia.com/2012/02/the-heart-failure-epidemic/ 
The relative proportion of cases with (grey bars) and 
without (red bars) preserved LV systolic function. 
Risk Factors and Etiology 
(Underlying Causes of Systolic Heart Failure) 1 
• Coronary artery disease 
• Diabetes mellitus 
• Hypertension 
• Valvular heart disease (stenosis or regurgitant 
lesions) 
• Arrhythmia (supraventricular or ventricular) 
• Infections and inflammation (myocarditis) 
emedicine.medscape.com/article/163062-overview#a4 
Risk Factors and Etiology 
(Underlying Causes of Systolic Heart Failure) 2 
• Peripartum cardiomyopathy 
• Congenital heart disease 
• Drugs (either recreational, such as alcohol 
and cocaine, or therapeutic drugs with 
cardiac side effects, such as doxorubicin) 
• Idiopathic cardiomyopathy 
• Rare conditions (endocrine abnormalities, 
rheumatologic disease, neuromuscular 
conditions) 
 emedicine.medscape.com/article/163062-overview#a4 
Risk Factors and Etiology 
(Underlying Causes of Diastolic Heart Failure) 
• Coronary artery disease 
• Diabetes mellitus 
• Hypertension 
• Valvular heart disease   
• Hypertrophic 
cardiomyopathy 
• Restrictive 
cardiomyopathy   
• Constrictive pericarditis 
medscape.org/viewarticle/491741_3 
Risk Factors and Etiology 
(Underlying Causes of Acute Heart Failure) 
• Acute valvular regurgitation 
• Myocardial infarction 
• Myocarditis 
• Arrhythmia 
• Drugs (e.g., cocaine, calcium 
channel blockers, or beta-
blocker overdose) 
• Sepsis 
nature.com/nrcardio/journal/v9/n8/fig_tab/nrcardio.2012.60_F1.html 
Risk Factors and Etiology 
(Underlying Causes of  High-Output Heart Failure) 
• Anemia 
• Systemic arteriovenous 
fistulas 
• Hyperthyroidism 
• Beriberi heart disease 
• Paget disease of bone 
• Fibrous dysplasia 
• Multiple myeloma 
• Pregnancy 
• Glomerulonephritis 
• Polycythemia vera 
• Carcinoid syndrome 
emedicine.medscape.com/article/163062-overview#a4 content.onlinejacc.org/article.aspx?articleid=1139115 
Risk Factors and Etiology 
(Underlying Causes of Right  Heart Failure) 
• Left ventricular failure 
• Coronary artery disease 
(ischemia) 
• Pulmonary hypertension 
• Pulmonary valve stenosis 
• Pulmonary embolism 
• Chronic pulmonary disease 
• Neuromuscular disease 
emedicine.medscape.com/article/163062-overview#a4 fairviewebenezer.org/HealthLibrary/Article/115854EN 
Risk Factors and Etiology 
(Fundamental Causes of Heart Failure) 
Fundamental causes include 
the biological mechanisms, 
through which either an 
increased hemodynamic 
burden or a reduction in 
oxygen delivery to the 
myocardium results in 
impairment of myocardial 
contraction. 
emedicine.medscape.com/article/163062-overview#a4 .scielo.br/scielo.php?pid=S0066-782X2014000500013&script=sci_arttext&tlng=en 
Risk Factors and Etiology 
(Precipitating Causes of Heart Failure) 
Overt heart failure may be 
precipitated by progression of 
the underlying heart disease 
(e.g., further narrowing of a 
stenotic aortic valve or mitral 
valve) or various conditions 
(fever, anemia, infection) or 
medications (chemotherapy, 
NSAIDs). 
emedicine.medscape.com/article/163062-overview#a4 eurheartj.oxfordjournals.org/content/early/2015/09/28/eurheartj.ehv513 
Risk Factors and Etiology 
(Genetic Causes of Heart Failure) 
• Dilated 
cardiomyopathy  
• Arrhythmic 
cardiomyopathy  
• Right ventricular 
cardiomyopathy  
• Restrictive 
cardiomyopathy. 
emedicine.medscape.com/article/163062-overview#a4 /circ.ahajournals.org/content/101/21/2490.figures-only 
Idiopathic Restrictive 
Cardiomyopathy, marked interstitial 
fibrosis 
 US MLE TEST 
A 60-year-old Caucasian male presents to your office 
complaining of shortness of breath on exertion. He 
undergoes an echocardiogram and is found to have an 
ejection fraction of 35%. Which of the following 
classes of drugs would improve mortality in this 
patient?  
1.  Cardiac glycosides  
2.  Calcium channel blockers  
3.  Thiazide diuretics  
4.  ACE inhibitors  
5.  Nitrates  
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
 US MLE TEST 
Correct Answer 4:  The patient in the question stem has 
systolic heart failure as evidenced by his decreased ejection 
fraction. Beta blockers, angiotensin converting enzyme (ACE) 
inhibitors, and angiotensin receptor blockers (ARBs) have 
been shown to decrease mortality in the treatment of systolic 
heart failure. Spironolactone and eplerenone have 
additionally been shown to provide a mortality benefit. 
Incorrect Answers: 
Although all of these drug classes may provide symptomatic 
relief in the treatment of systolic heart dysfunction, of the 
choices listed, only ACE inhibitors improve mortality. 
 
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
Mechanisms   
(The Common Pathophysiologic State)   1  
 en.wikipedia.org/wiki/Heart_failure#Causes http://emedicine.medscape.com/article/163062-overview#a3 
• The heart in HF may have a reduced force of 
contraction due to overloading of the ventricle 
with fails the Frank–Starling law. 
• A reduced stroke volume (SV) may occur as a 
result of a failure of systole, diastole or both, 
that contributes to the exercise intolerance 
commonly seen in HF.  
Mechanisms   
(The Common Pathophysiologic State)   2 
 en.wikipedia.org/wiki/Heart_failure#Causes http://emedicine.medscape.com/article/163062-overview#a3 
• A common finding in HF is an increased 
sympathetic  and  renin-angiotensin-
aldosterone system (RAAS) activity with other 
neurohumoral adjustments that leads to salt 
and water retention, resulting in deep 
disturbances of heart function and structure 
with enlargement of the ventricles and their 
remodeling.   
Mechanisms   
(The Common Pathophysiologic State)   3 
 en.wikipedia.org/wiki/Heart_failure#Causes http://emedicine.medscape.com/article/163062-overview#a3 
• This increases the risk of cardiac arrest 
(specifically due to abnormal ventricular heart 
rhythms), and reduces blood supply to the rest 
of the body.    
 
Mechanisms   
(Myocytes and Myocardial Remodeling) 1     
 emedicine.medscape.com/article/163062-overview#a3 
• In the HF, increased myocardial volume is 
characterized by larger myocytes approaching 
the end of their life cycle and  as more 
myocytes drop out, an increased load is placed 
on the remaining myocardium, and this 
unfavorable environment is transmitted to the 
progenitor cells responsible for replacing lost 
myocytes.  
Mechanisms   
(Myocytes and Myocardial Remodeling) 2     
 emedicine.medscape.com/article/163062-overview#a3 
• Progenitor cells become progressively less 
effective as the underlying pathologic process 
worsens and myocardial failure accelerates.  
• This results in cellular proliferation, adverse 
myocardial remodeling, and antinatriuresis, 
with total body fluid excess and worsening of 
heart failure symptoms. 
Mechanisms   
(Left Ventricle Stiffness)   1   
 emedicine.medscape.com/article/163062-overview#a3 
• An increase in LV stiffness occurs secondary to 
any one of, or any combination of, the following 
3 mechanisms:  
• rise in filling pressure,  
• shift to a steeper ventricular pressure-volume 
curve,  
• decrease in ventricular distensibility.  
Mechanisms   
(Left Ventricle Stiffness)   2 
 emedicine.medscape.com/article/163062-overview#a3 
• A shift to a steeper ventricular pressure-volume 
curve results, most commonly, not only from 
increased ventricular mass and wall thickness 
but also from infiltrative, endomyocardial 
fibrosis, and myocardial ischemia. 
• Parallel upward displacement of the diastolic 
pressure-volume curve is generally referred a 
decrease in ventricular distensibility that caused 
by extrinsic compression of the ventricles. 
Mechanisms   
(Concentric Left Ventricle Hypertrophy) 1     
 emedicine.medscape.com/article/163062-overview#a3 
• Pressure overload that leads to concentric LV 
hypertrophy (LVH), shifts the diastolic 
pressure-volume curve to the left along its 
volume axis and ventricular diastolic pressure 
is abnormally elevated, although chamber 
stiffness may or may not be altered.  
Mechanisms   
(Concentric Left Ventricle Hypertrophy) 2     
 emedicine.medscape.com/article/163062-overview#a3 
• Increases in diastolic pressure lead to 
increased myocardial energy expenditure, 
remodeling of the ventricle, increased 
myocardial oxygen demand, myocardial 
ischemia, and eventual progression of the 
maladaptive mechanisms of the heart that 
lead to decompensated HF. 
Mechanisms   
(Systolic dysfunction)     
 en.wikipedia.org/wiki/Heart_failure#Causes 
• HF caused by systolic dysfunction is characterized by a 
decreased ejection fraction (less than 45%).  
• The strength of ventricular contraction is attenuated and 
inadequate for creating an adequate stroke volume, resulting 
in inadequate cardiac output.  
• Because the ventricle is inadequately emptied, ventricular end-
diastolic pressure and volumes increase and this is transmitted 
to the atrium.  
• On the left side of the heart it causing pulmonary edema and 
on the right side of the heart it resulting in 
dependent peripheral edema. 
Mechanisms   
(Diastolic dysfunction)  1    
 en.wikipedia.org/wiki/Heart_failure#Causes 
• HF caused by diastolic dysfunction is generally 
described as the backward failure of the 
ventricle to adequately relax and typically 
denotes a stiffer ventricular wall with 
inadequate filling of the ventricle, and 
therefore inadequate SV.   
Mechanisms   
(Diastolic dysfunction)  2    
 en.wikipedia.org/wiki/Heart_failure#Causes 
• Diastolic dysfunction can be caused by 
processes similar to those that cause systolic 
dysfunction, particularly causes that affect 
cardiac remodeling. 
• The patient may be completely asymptomatic 
at rest, but is exquisitely sensitive to increases 
in heart rate, and sudden bouts of tachycardia  
may result in flash pulmonary edema.   
Mechanisms   
(Arrhythmias)   1  
 emedicine.medscape.com/article/163062-overview#a3 
• Arrhythmia imparts a significant burden in all 
forms of HF.  
• The most significant of all rhythms associated 
with HF are the life-threatening ventricular 
arrhythmias.  
• Structural substrates for ventricular 
arrhythmias regardless of the underlying 
cause, include ventricular dilatation, 
myocardial hypertrophy, and myocardial 
fibrosis.  
Mechanisms   
(Arrhythmias)   2 
 emedicine.medscape.com/article/163062-overview#a3 
• At the cellular level, myocytes may be 
exposed to increased stretch, wall tension, 
catecholamines, ischemia, and electrolyte 
imbalance.  
• The combination of these factors contributes 
to an increased incidence of arrhythmogenic 
sudden cardiac death in patients with heart 
failure. 
Mechanisms   
(Pressure–Volume Loops in Heart Failure ) 1    
• Pressure–volume loop 
(PVL)characteristics in HF with 
preserved (black) ejection fraction 
(EF)and HF with reduced (red)  EF in 
baseline conditions (A), and in 
response to vasodilators (B).  
• (A) Curved arrow depicts the 
steeper end-systolic pressure–
volume relationship in HF with 
preserved EF compared with HF 
with reduced EF.   eurheartj.oxfordjournals.org/content/35/16/1022 
Mechanisms   
(Pressure–Volume Loops in Heart Failure ) 2   
• (B) PVL before (solid) and after 
(dotted) administration of 
vasodilators.  
• Arrows contrast the drop in blood 
pressure and changes in stroke 
volume between HF with 
preserved EF and HF with reduced 
EF in response to vasodilators. 
eurheartj.oxfordjournals.org/content/35/16/1022 
Mechanisms   
(HF affects the Systems involved in the Physiological Response) 1     
• Severely compromised 
cardiac function is a 
primary 
pathophysiological 
component in HF.  
.scielo.br/scielo.php?script=sci_arttext&pid=S1413-35552008000200002 
Mechanisms   
(HF affects the Systems involved in the Physiological Response) 2     
• Patients with HF 
frequently present 
reduced capillary 
density and intrinsic 
skeletal muscle 
abnormalities, primarily 
in the form of diminished 
aerobic (mitochondrial) 
function. 
.scielo.br/scielo.php?script=sci_arttext&pid=S1413-35552008000200002 
 US MLE TEST 
A 68-year-old male suffered a myocardial infarction two weeks 
ago. Since this incident, he has reported increased shortness of 
breath with both activity as well as when lying flat; he has also 
noted increased swelling in his ankles. Physical exam is 
significant for an S3 gallop on cardiac auscultation, bibasilar 
crackles on lung auscultation, and 2+ edema of the bilateral 
ankles. Which of the following sets of cardiac parameters would 
most likely be associated with this patient's current condition? 
(Cardiac index = CI; Systemic vascular resistance = SVR; Left 
ventricular end diastolic pressure = LVEDP) 
1.  Decreased CI, decreased SVR, increased LVEDP, 2.  Decreased 
CI, increased SVR, decreased LVEDP, 3.  Decreased CI, increased 
SVR, increased LVEDP, 4.  Increased CI, decreased SVR, increased 
LVEDP, 5.  Increased CI, increased SVR, decreased LVEDP  
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
 US MLE TEST 
Correct Answer 3:  This patient is suffering from systolic heart 
failure. He would be expected to have a decreased cardiac 
index, increased systemic vascular resistance, and increased 
left ventricular end diastolic pressure. 
Incorrect Answers: 
1: Decreased systemic vascular resistance occurs due to 
systemic vasodilation, which may be a sequela of sepsis (most 
common), pancreatitis, cirrhosis, adrenal insufficiency, head 
injury, or beriberi., 2: Decreased LVEDP occurs in mitral 
stenosis., 4 & 5: Increased cardiac index may be seen in 
patients suffering from high-output cardiac failure; causes of 
this may include AV fistula, anemia, hyperthyroidism, beriberi, 
renal disease, hepatic disease, or sepsis. 
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
Classification 
(International Classification of Diseases (ICD)) 
icd10coded.com/cm/ch9/I20-I25/ 
Chapter IX 
Other forms of heart disease 
(I30-I52) 
 150 Heart failure 
          I50.0 Congestive heart failure, right 
ventricular failure  
         I50.1Left ventricular failure 
          I50.9 Heart failure, unspecified 
Classification 
(New York Heart Association Functional Classification) 
en.wikipedia.org/wiki/New_York_Heart_Association_Functional_Classification 
NYHA Class Symptoms 
I 
Cardiac disease, but no symptoms and no limitation in 
ordinary physical activity, e.g. no shortness of breath 
when walking, climbing stairs etc. 
II 
Mild symptoms (mild shortness of breath and/or angina) 
and slight limitation during ordinary activity. 
III 
Marked limitation in activity due to symptoms, even 
during less-than-ordinary activity, e.g. walking short 
distances (20–100 m). 
Comfortable only at rest. 
IV 
Severe limitations. Experiences symptoms even while at 
rest. Mostly bedbound patients. 
Classification 
(Stages of Heart Failure) 
heartfailurecenter.com/hfcheartfailurestages.shtm 
HF Stages Symptoms 
A 
No objective evidence of cardiovascular disease. No 
symptoms and no limitation in ordinary physical activity. 
B 
Objective evidence of minimal cardiovascular disease. Mild 
symptoms and slight limitation during ordinary activity. 
Comfortable at rest. 
C 
Objective evidence of moderately severe cardiovascular 
disease. Marked limitation in activity due to symptoms, even 
during less-than-ordinary activity. Comfortable only at rest. 
D 
Objective evidence of severe cardiovascular disease. Severe 
limitations. Experiences symptoms even while at rest. 
Classification 
( Killip classification for  Acute Myocardial Infarction) 
heartfailurecenter.com/hfcheartfailurestages.shtm 
Killip Class Symptoms 
I 
Individuals with no clinical signs of heart failure (mortality 
6%). 
II 
 Individuals with rales or crackles in the lungs, an S3, and 
elevated jugular venous pressure (mortality 17%). 
III 
Individuals with frank acute pulmonary edema (mortality 
38%). 
IV 
Individuals in cardiogenic shock or hypotension, and 
evidence of peripheral vasoconstriction (mortality 67%). 
Clinical Investigation  
(Signs and Symptoms) 1 
• Exertional dyspnea and/or dyspnea at rest. 
• Orthopnea. 
• Acute pulmonary edema. 
• Chest pain/pressure and palpitations. 
• Tachycardia. 
• Fatigue and weakness. 
• Nocturia and oliguria. 
• Anorexia, weight loss, nausea. 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Clinical Investigation  
(Signs and Symptoms) 2 
• Exophthalmos and/or visible pulsation of eyes. 
• Distention of neck veins. 
• Weak, rapid, and thready pulse. 
• Rales, wheezing. 
• S 3 gallop and/or pulsus alternans 
• Increased intensity of P 2 heart sound. 
• Hepatojugular reflux. 
• Ascites, hepatomegaly, and/or anasarca. 
• Central or peripheral cyanosis, pallor. 
 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Clinical Investigation  
(Price of Signs and Symptoms) 1 
• Symptoms are often non-
specific and do not help 
discriminate between HF 
and other problems. 
• Symptoms due to fluid 
retention may resolve 
quickly with diuretic 
therapy.   
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms  
Clinical Investigation  
(Price of Signs and Symptoms) 2 
• Signs, such as elevated 
jugular venous pressure 
and displacement of the 
apical impulse, may be 
more specific, but are 
harder to detect and have 
poor reproducibility. 
• Etc. 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms  
Clinical Investigation  
(Clinical Portrait of Congestive HF) 
medical-dictionary.thefreedictionary.com/heart+failure 
Diagnosis 
(Diagnostic algorithm of Non-Acute HF) 
  
• Diagnostic algorithm for a 
diagnosis of HF of non-
acute onset 
• BNP - B-type natriuretic 
peptide; CAD - coronary 
artery disease; MI - 
myocardial infarction; NT-
proBNP - N-terminal pro-B 
type natriuretic peptide.  
  eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Diagnosis 
(The Framingham Major Criteria for the Diagnosis of HF) 
• Paroxysmal nocturnal 
dyspnea 
• Weight loss of 4.5 kg 
in 5 days in response 
to treatment 
• Neck vein distention 
• Rales 
• Acute pulmonary 
edema 
• Hepatojugular reflux 
• S 3 gallop 
• Central venous pressure 
greater than 16 cm water 
• Circulation time of 25 
seconds 
• Radiographic 
cardiomegaly 
• Pulmonary edema, 
visceral congestion 
 
 emedicine.medscape.com/article/155919-treatment#d5 
Diagnosis 
(The Framingham Minor Criteria for the Diagnosis of HF) 
• Nocturnal cough 
• Dyspnea on ordinary exertion 
• A decrease in vital capacity by one third the 
maximal value recorded 
• Pleural effusion 
• Tachycardia (rate of 120 bpm) 
• Bilateral ankle edema 
 emedicine.medscape.com/article/155919-treatment#d5 
Diagnosis 
(The Initial Evaluation for Suspected Heart Failure) 1 
• Complete blood count (CBC) 
• Urinalysis 
• Electrolyte levels 
• Renal and liver function studies 
• Fasting blood glucose levels 
• Lipid profile 
• Thyroid stimulating hormone (TSH) levels 
• B-type natriuretic peptide levels 
 
 emedicine.medscape.com/article/155919-treatment#d5 
Diagnosis 
(The Initial Evaluation for Suspected Heart Failure) 2 
• N-terminal pro-B-type natriuretic peptide 
• Electrocardiography 
• Chest radiography 
• 2-dimensional (2-D) echocardiography 
• Nuclear imaging  
• Maximal exercise testing 
• Pulse oximetry or arterial blood gas 
 
 emedicine.medscape.com/article/155919-treatment#d5 
Diagnosis 
(Natriuretic Peptide Cutoff Values for Acute decompensated HF) 
  
dovepress.com/cardiopulmonary-laboratory-biomarkers-in-the-evaluation-of-acute-dyspn-peer-reviewed-fulltext-article-OAEM 
ACEP -American College of Emergency Physicians, 
CKD – chronic kidney disease, BMI  - body mass 
index  
Diagnosis 
(Electrocardiography) 
  
ucsf.edu/news/2013/04/105041/routine-ekg-finding-could-signal-serious-heart-problem 
• The top ECG shows a reading 
of a person with a healthy 
heart.  
• The bottom ECG shows a 
reading of a person with left 
anterior fascicular block 
(LAFB), previously thought to 
be benign but found to 
potentially signal a serious 
HF. 
Diagnosis 
(Chest Radiography) 
  
Chest X-Ray signs of HF 
radiologyassistant.nl/en/p4c132f36513d4/chest-x-ray-heart-failure.html 
Views of the upper lobe vessels of a 
patient in good condition (left) and during 
a period of CHF (right). Notice also the 
increased width of the vascular pedicle 
(red arrows). 
Diagnosis 
(Transthoracic Echocardiography ) 
  
elsevier.es/en-revista-revista-portuguesa-cardiologia-english-edition--434-articulo-systemic-sclerosis-a-rare-cause-90443802 
Mild LV dilation (end-diastolic diameter 55 mm, end-systolic diameter 
49 mm), normal LV thickness, asynchronous LV wall motion, LV ejection 
fraction, LV diastolic dysfunction (restrictive pattern), right ventricular 
(RV) dilation and impaired RV systolic function (tricuspid annular plane 
systolic excursion 9 mm), without evidence of significant pulmonary 
hypertension.  
 US MLE TEST 
A 69-year-old is hospitalized for worsening dyspnea at rest. 
Physical examination is notable for crackles at both lung bases 
and 2+ edema at the ankles bilaterally. Current medications 
include losartan, metoprolol, furosemide and spironolactone. 
An EKG and echocardiography are ordered. Which of the 
following results would serve as the best indication for 
placement of an implantable cardioverter defibrillator (ICD) in 
this patient? 
1.  Supraventricular tachycardia on EKG  
2.  Atrial fibrillation on EKG  
3.  Reduced diameter of aortic valve on echocardiography  
4.  Reduced left ventricular ejection fraction on 
echocardiography  
5.  Left ventricular hypertrophy on echocardiography  
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
 US MLE TEST 
Correct Answer 4: The single best indication for placement of 
an ICD in an adult is an ejection fraction less than 35%. 
Incorrect Answers: 
1: Supraventricular tachycardia on EKG should be converted 
to sinus rhythm in the acute setting. 
2: Atrial fibrillation indicates a need for anticoagulation 
therapy in patients with heart failure. 
3: Aortic stenosis as a cause of heart failure is an indication 
for valve replacement.  
5: Left ventricular hypertrophy is commonly seen in heart 
failure, but is not in itself an indication for ICD placement. 
 
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
Treatment 
(General Principles) 1 
• The goals of treatment in patients with HF are 
to improve their clinical status, functional 
capacity and quality of life, prevent hospital 
admission and reduce mortality.  
• Treatment include lifestyle and 
pharmacological modalities with occasionally 
various forms of device therapy and rarely 
cardiac transplantation.  
en.wikipedia.org/wiki/Heart_failure#Management eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(General Principles) 2 
• In acute decompensated HF, the immediate 
goal is to re-establish adequate perfusion and 
oxygen delivery to end organs, that involve 
some combination of vasodilators, diuretic, 
and possibly non invasive positive pressure 
ventilation (NIPPV).  
en.wikipedia.org/wiki/Heart_failure#Management eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Lifestyle modification) 1 
• Behavioral modification is a primary 
consideration in any chronic HF management 
program, with dietary guidelines 
regarding fluid and salt intake being of 
particular importance.  
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Lifestyle modification) 2 
• Exercise should be encouraged and tailored to 
suit individual capabilities: the inclusion of 
regular physical conditioning as part of a 
cardiac rehabilitation program can 
significantly improve quality of life and reduce 
the risk of hospital admission for worsening 
symptoms however there is no evidence for a 
reduction in mortality rates as a result of 
exercise.   
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Lifestyle modification) 3 
• Home visits and regular monitoring at HF 
clinics reduce the need for hospitalization and 
improve life expectancy. 
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Pharmacological Modalities: 1) 
• First-line therapy due to reduced systolic function 
should include angiotensin-converting enzyme (ACE) 
inhibitors (ACE-I) or angiotensin receptor 
blockers (ARBs), and beta-adrenergic blocking 
agents (beta blockers).  
• In people who are intolerant of ACE-I and ARBs or who 
have significant kidney dysfunction, the use of 
combined hydralazine and a long-acting nitrate; it is 
especially beneficial in African-Americans. 
• In patients with markedly reduced ejection fraction in 
addition to beta blockers and ACE-I, should be used of 
an aldosterone antagonist.  
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Pharmacological Modalities: 2) 
• Second-line drug HF digitalis do not confer a 
mortality benefit.  
• Diuretics have been a mainstay of treatment for 
patients with fluid accumulation, and include 
diuretics classes such as loop diuretics, thiazide-like 
diuretic, and potassium-sparing diuretic.  
• A new therapeutic class of agents: angiotensin 
receptor neprilysin inhibitor (ARNI),   If-channel 
inhibitor (ivabradin. 
•  Treating  with parenteral iron if anemia is found.  
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Algorithm for a Patient with Symptomatic HF and reduced EF) 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin-Converting Enzyme Inhibitors) 1 
• ACE-I have been shown to reduce mortality 
and morbidity in patients and are 
recommended unless contraindicated or not 
tolerated in all symptomatic patients.  
• ACE-I should be up-titrated to the maximum 
tolerated dose in order to achieve adequate 
inhibition of  RAAS.  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin-Converting Enzyme Inhibitors) 2 
• There is evidence that in clinical practice the 
majority of patients receive suboptimal doses 
of ACE-I. 
• ACE-I are also recommended in patients with 
asymptomatic LV systolic dysfunction to 
reduce the risk of HF development, HF 
hospitalization and death. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin II type I receptor blockers) 
• ARBs are recommended only as an alternative 
in patients intolerant of an ACE-Is. 
• The combination of ACEI/ARBs for HF was 
reviewed by the European Medical Association, 
which suggested that benefits are thought to 
outweigh risks only in a select group of patients 
in whom other treatments are unsuitable.   
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Beta-Blockers) 1 
• There is consensus that beta-blockers and ACE-I 
are complementary, and can be started 
together as soon as the diagnosis of HF with 
reduce EF is made.  
• Beta-blockers should be initiated in clinically 
stable patients at a low dose and gradually up-
titrated to the maximum tolerated dose.  
• Beta-blockers should be considered for rate 
control in patients with HF and AF, especially in 
those with high heart rate.  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Beta-Blockers) 2 
• Beta-blockers are recommended in patients 
with a history of myocardial infarction and 
asymptomatic LV systolic dysfunction to reduce 
the risk of death 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Mineralocorticoid/Aldosterone Receptor Antagonists) 
• Mineralocorticoid/aldosterone receptor antagonists 
(spironolactone and eplerenone) block receptors that 
bind aldosterone and, with different degrees of affinity, 
other steroid hormone (e.g. corticosteroids, androgens) 
receptors.  
• Spironolactone or eplerenone are recommended in all 
symptomatic patients (despite treatment with an ACE-I 
and a beta-blocker) with HF and LVEF ≤35%, to reduce 
mortality and HF hospitalization. 
• Regular checks of serum potassium levels and renal 
function should be performed according to clinical 
status. eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Diuretics) 1 
• Diuretics are recommended to reduce the signs 
and symptoms of congestion in patients with 
HF. 
• Loop diuretics produce a more intense and 
shorter diuresis than thiazides, although they 
act synergistically and the combination may be 
used to treat resistant oedema.  
• The aim of diuretic therapy is to achieve and 
maintain euvolemia with the lowest achievable 
dose.   
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Diuretics) 2 
• The dose of the diuretic must be adjusted 
according to the individual needs over time.  
• Patients can be trained to self-adjust their 
diuretic dose based on monitoring of 
symptoms/signs of congestion and daily weight 
measurements. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin Receptor Neprilysin Inhibitor) 
•  Angiotensin receptor neprilysin inhibitor (ARNI) 
is a  new class of agents acting on the RAAS and 
the neutral endopeptidase. 
• The first in class is LCZ696, which is a molecule 
that combines the moieties of valsartan and 
sacubitril (neprilysin inhibitor) in a single 
substance.  
• Neprilysin inhibiting enhancing diuresis, 
natriuresis and myocardial relaxation and anti-
remodelling.  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(If-channel inhibitor) 1 
• Ivabradine slows the 
heart rate through 
inhibition of 
the If channel in the 
sinus node and 
therefore should only be 
used for patients in 
sinus rhythm.   
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 drsvenkatesan.com/tag/ivabradine/ 
Treatment 
(If-channel inhibitor) 2 
• Ivabradine reduced the 
combined endpoint of 
mortality and 
hospitalization  in 
patients with 
symptomatic HF and LV 
EF ≤35%, in sinus 
rhythm and with a heart 
rate ≥70 beats per 
minute (bpm).  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 drsvenkatesan.com/tag/ivabradine/ 
Treatment 
(Not Recommended) 
• Hydroxy-3-methylglutaryl-
coenzyme A reductase 
(‘statins’). 
• Oral anticoagulants and 
antiplatelet therapy. 
• Renin inhibitors. 
• Calcium-channel blockers. 
 
 eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 consumerreports.org/cro/2014/03/treating-high-cholesterol-with-statins/index.htm 
Treatment 
(Interventional Treatment) 
• Implantable cardioverter-defibrillator. 
• Cardiac resynchronization therapy. 
• Revascularization procedures. 
• Valve replacement/repair. 
• Ventricular restoration. 
• Extracorporeal membrane 
oxygenation. 
• Ventricular assist devices. 
• Heart transplantation. 
• Total artificial heart. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 emedicine.medscape.com/article/163062-overview#a1 www.azheartrhythmcenter.com/procedures/ 
Treatment 
(Palliative Care) 
The growing number of 
patients with Stage IV HF 
(intractable symptoms of 
fatigue, shortness of breath 
or chest pain at rest despite 
optimal medical therapy) 
should be considered for 
palliative care or hospice, 
according to American 
College of 
Cardiology/American Heart 
Association guidelines. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 www.eapcnet.eu/Themes/Specificgroups/Heartdisease.aspx 
 US MLE TEST 
A 69-year-old male presents to the emergency department with 
shortness of breath. The patient has presented three times this past 
month with similar complaints. The patient sees no primary care 
physician and is currently not taking any medications. The patient 
states his shortness of breath started when he was walking from his 
car to a local restaurant. His temperature is 99.5°F (37.5°C), pulse is 
100/min, blood pressure is 130/90 mmHg, respirations are 18/min, 
and oxygen saturation is 96% on room air. On physical exam you note 
a fatigued appearing gentleman. Cardiovascular exam reveals an 
additional heart sound after S2. Pulmonary exam is notable for 
bilateral crackles. Abdominal exam reveals an obese abdomen 
without pain in any of the quadrants. Lower extremity pitting edema 
is noted bilaterally. Which of the following sets of lab values most 
likely corresponds to this patient's presentation?  
1.  High BNP, high ADH, high sodium, high potassium, 2.  High BNP, 
low ADH, normal sodium, low potassium, 3.  High BNP, high ADH, low 
sodium, low potassium, 4.  Low BNP, high ADH, low sodium, low 
potassium, 5.  Low BNP, low ADH, normal sodium, normal potassium 
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
 US MLE TEST 
Correct Answer 3: This patient is presenting with symptoms of 
congestive heart failure (CHF). The most likely laboratory abnormalities 
are elevated brain natriuretic peptide (BNP), high anti-diuretic hormone 
(ADH), low sodium, and low potassium. 
Incorrect Answers: 
1: High BNP, high ADH, high sodium, and high potassium does not reflect 
the changes that would be seen in CHF. Answer 2: High BNP, low ADH, 
normal sodium, and low potassium does not reflect the appropriate 
increase in ADH and subsequent decrease in sodium that would be seen 
in CHF., 4: Low BNP, high ADH, low sodium, and low potassium does not 
reflect the finding of elevated BNP that is classically found in the dilated 
ventricles of CHF., 5: Low BNP, low ADH, normal sodium, and normal 
potassium reflects the findings in a healthy patient. 
https://www.medbullets.com/step1-endocrine/9019/pheochromocytoma 
Prognosis 1 
• Prognosis in HF can be assessed in multiple 
ways including clinical prediction rules and 
cardiopulmonary exercise testing. 
• HF is associated with significantly reduced 
physical and mental health, resulting in a 
markedly decreased quality of life. 
• Although some people survive many years, 
progressive disease is associated with an 
overall annual mortality rate of 10%.  
en.wikipedia.org/wiki/Heart_failure#Prognosis 
Prognosis 2 
• Approximately 18 of every 1000 persons will 
experience an ischemic stroke during the first 
year after diagnosis of HF. 
•  As the duration of follow-up increases, the 
stroke rate rises to nearly 50 strokes per 1000 
cases of HF by 5 years.[ 
en.wikipedia.org/wiki/Heart_failure#Prognosis 
Prophylaxis 
• A person's risk of developing HF is inversely 
related to their level of physical activity.  
• Those who achieved at least 500 MET-
minutes/week (the recommended minimum 
by U.S. guidelines) had lower HF risk than 
individuals who did not report exercising 
during their free time; the reduction in heart 
failure risk was even greater in those who 
engaged in higher levels of physical activity 
than the recommended minimum. 
en.wikipedia.org/wiki/Heart_failure#Prevention 
Abbreviations  
• ACE - angiotensin converting enzyme  
• ACE-Is - angiotensin converting enzyme 
blockers  
• ACEP -American College of Emergency 
Physicians 
• ARBs - angiotensin receptor blockers  
• ARNI -angiotensin receptor neprilysin 
inhibitor 
• BMI  - body mass index  
• BNP – Brain (B-type) natriuretic peptide 
• Bpm - beats per minute  
• CAD - coronary artery disease 
• CKD – chronic kidney disease 
• ECG – electrocardiography 
• EF - ejection fraction  
• HFpEF – HF with preserved EF 
• HR - heart rate  
• HF – heart failure 
• PVL - pressure–volume loop  
• ICD - International Classification of 
Diseases  
• LV - left ventricle  
• LVH - LV hypertrophy 
• MI - myocardial infarction 
• NOS - Not Otherwise Specified  
• NT- proBNP - N-terminal pro-B type 
natriuretic peptide 
• PVL - pressure–volume loop 
• RAAS - renin-angiotensin-aldosterone 
system   
• RV - right ventricle 
• SV - stroke volume   
 
 
 
 
Diagnostic and treatment guidelines 
• 2016 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure 
• Treatment of heart failure in adult congenital heart disease: a 
position paper of the Working Group of Grown-Up Congenital 
Heart Disease and the Heart Failure Association of the 
European Society of Cardiology 
• 2013 ACCF/AHA Guideline for the Management of Heart 
Failure 
 
 
 
